Interferon-beta 1a does not reduce expression of CCR5 and CXCR3 on circulating T cells.
The expression of CCR5 and CXCR3, two chemokine receptors involved with homing of T cells to inflamed tissue, was examined longitudinally on CD4+ and CD8+ T cells in patients with a first demyelinating event of the central nervous system (CNS) randomized to receive i.m. injections of interferon-beta1a (IFN-beta1a) or placebo. Blood for analysis was collected before and 48 h after injection at baseline and after 3 and 12 months of treatment. The results showed that treatment with IFN-beta1a did not affect numbers of T cells expressing CCR5 and CXCR3 during the first 12 months of treatment, either at the peak of biological response or at the trough of interferon effect, at steady-state.
Kivisäkk
Pia
P
Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Cotleur
Anne C
AC
Lee
Jar Chi
JC
Rudick
Richard A
RA
Ransohoff
Richard M
RM
D016516:CD4-CD8 Ratio / Q000706:statistics & numerical data; D015536:Down-Regulation / Q000276:immunology; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D007273:Injections, Intramuscular; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage*; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology; D019713:Receptors, CCR5 / Q000096:biosynthesis* / Q000097:blood; D054367:Receptors, CXCR3; D019707:Receptors, Chemokine / Q000096:biosynthesis* / Q000097:blood; D016176:T-Lymphocyte Subsets / Q000276:immunology* / Q000378:metabolism*; D013997:Time Factors
C515187:CXCR3 protein, human; D019713:Receptors, CCR5; D054367:Receptors, CXCR3; D019707:Receptors, Chemokine; D016899:Interferon-beta; D000068556:Interferon beta-1a